Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02822079
Other study ID # MAY2013-02-01
Secondary ID NCI-2015-00558HH
Status Recruiting
Phase Phase 1
First received June 28, 2016
Last updated October 28, 2016
Start date June 2016

Study information

Verified date July 2016
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best dose of deoxyribonucleic acid (DNA) vaccine therapy in treating patients with hepatitis C virus (HCV) infection that persists or progresses over a long period of time. Vaccines made from DNA may help the body build an effective immune response to kill cancer cells that express HCV infection.


Description:

PRIMARY OBJECTIVES:

I. To determine the safety profile of the HCV DNA vaccine, consisting of INO-8000 (HCV antigen DNA) alone or co-administered with INO-9012 (interleukin [IL]-12 adjuvant DNA) (DNA plasmid encoding interleukin-12 INO-9012) II. To identify a dose of INO-9012 (IL-12 adjuvant DNA) for co-administration with INO-8000 (HCV antigen DNA) based on induction of HCV-specific interferon (IFN)-gamma production by peripheral blood mononuclear cells at 26 weeks compared to baseline in HCV-infected participants.

SECONDARY OBJECTIVES:

I. Determine the rate at which INO-8000 with different doses of INO-9012 induces a > 1 log decrease (or undetectable) in HCV RNA level at weeks 14 and 26.

II. Determine the rate at which INO-8000 with different doses of INO-9012 induces an end-of-treatment undetectable HCV ribonucleic acid (RNA) (end-of-treatment virologic response - EVR) at 26 weeks and a sustained virologic response (SVR) at 36 weeks.

III. Determine the rate at which INO-8000 with different doses of INO-9012 induces other parameters of cluster of differentiation (CD)8 and CD4 T lymphocyte responses as measured by flow cytometry, and antibody responses to HCV antigen at weeks 14 and 26.

OUTLINE: This is a dose-escalation study of INO-9012.

Patients receive INO-8000 intramuscularly (IM) and DNA plasmid encoding interleukin-12 INO-9012 IM (dose levels 2-4) followed by electroporation (EP) at day 0 and at weeks 4, 12, and 24.

After completion of study treatment, patients are followed up at weeks 48 and 76.


Recruitment information / eligibility

Status Recruiting
Enrollment 32
Est. completion date
Est. primary completion date March 2020
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- PRE-REGISTRATION INCLUSION CRITERIA

- Presence of chronic HCV infection; note: chronic HCV infection is defined by (1) presence of plasma or serum HCV RNA in a participant with HCV antibody for >= 180 days, or (2) two documented HCV RNA positive results >= 180 days apart, OR (3) positive HCV RNA with biopsy demonstrating chronic hepatitis

- Willingness to use adequate contraception to avoid pregnancy or impregnation for the duration of study participation; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; for men and women who are not postmenopausal [i.e., >= 12 months of non-therapy-induced amenorrhea, confirmed by follicle stimulating hormone (FSH), if not on hormone replacement] or surgically sterile (vasectomy in males or absence of ovaries and/or uterus in females), agreement to remain abstinent or use highly effective or combined contraceptive methods that result in a failure rate of < 1% per year during the treatment period and at least through week 12 after last dose; abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the subject; periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception; examples of contraceptive methods with an expected failure rate of < 1% per year include male sterilization and hormonal implants; alternatively, proper use of combined oral or injected hormonal contraceptives and certain intrauterine devices or two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of < 1% per year (barrier methods must always be supplemented with the use of a spermicide); should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately; should a female partner of a male study participant become pregnant while the male participant is on study, the male participant should inform his study physician immediately

- Willingness to avoid excessive use of alcohol during the study; note: excessive use is defined as drinking >= 8 alcoholic drinks per week on average

- Willingness to provide blood samples for research tests specified in the protocol

- Ability to understand and willingness to sign a written informed consent document

- REGISTRATION INCLUSION CRITERIA

- Serum or plasma HCV RNA level >= 10,000 IU/mL

- Screening HCV genotype, demonstrating genotype 1

- Alpha feto protein (AFP) levels within normal institutional limits or judged to be not clinically significant by the investigator; Exception: If deemed clinically significant, then liver imaging must be available within previous 6 months (e.g., ultrasound, computed tomography [CT] scan, magnetic resonance imaging [MRI]) showing no evidence of hepatocellular carcinoma

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

- Screening laboratory values (serum chemistry, hematology, prothrombin time [PT](international normalized ratio [INR])/activated partial thromboplastin time [APTT], and creatine phosphokinase [CPK]) obtained up to 28 days prior to administration of first vaccine injection on Day 0 within institutional normal range or judged to be not clinically significant by principal investigator (PI) and medical monitor

- 12-lead electrocardiogram (ECG) showing normal heart rhythm; note: if there are abnormalities, then the abnormalities must be deemed of no clinical significance

Exclusion Criteria:

- PRE-REGISTRATION EXCLUSION CRITERIA

- Failure of previous HCV therapies

- Human immunodeficiency virus (HIV) infection

- Any previous treatment for HCV =< 6 months prior to registration

- Other uncontrolled immune-compromising illness

- Autoimmune disorders, transplant recipients, other immunosuppression including any concurrent condition requiring the use of immunosuppressive/ immunomodulating agents; Exception: eye drop-containing and infrequent inhaled corticosteroids are permissible; topical corticosteroids are permissible at locations other than the administration site (upper arm); Note: All systemic corticosteroids must be discontinued at least 4 weeks prior to randomization; inhaled corticosteroids must be discontinued >= 48 hours prior to randomization and courses of more than 2 weeks are not permissible within 4 weeks of randomization

- Ongoing hepatitis B virus (HBV) infection

- Documented evidence of fibrosis or cirrhosis (Metavir 2, 3, and 4) and subjects with significant extrahepatic manifestations of hepatitis C (such as cryoglobulinemia with symptoms or evidence of end-organ manifestations, renal disease, type 2 diabetes, or porphyria cutanea tarda

- Other known causes of significant liver disease including chronic or acute hepatitis B, acute hepatitis A, hemochromatosis, or homozygote alpha-1 antitrypsin deficiency

- Active malignancy; exception: non-melanoma skin cancers cancer(s) for which diagnosis and treatment was completed >= 3 years prior to pre-registration

- History of major organ transplantation with an existing functional graft

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

- History of cardiac arrhythmia, controlled or uncontrolled, including ventricular and supraventricular arrhythmia

- Pregnant or nursing women; breastfeeding should be discontinued if the mother is treated with INO-8000

- Current diagnosis or history of cardiac pre-excitation syndromes (e.g. Wolff-Parkinson-White)

- Metal implants on same limb as intended administration site

- Tattoos, scars, active lesions, or rashes =< 2 cm of the intended site of study treatment

- Documentation of history of seizure within previous 5 years

- Pacemaker or other implanted device

- Any condition that, in the clinical judgement of the investigator, would place a participant at unreasonably increased risk

- REGISTRATION EXCLUSION CRITERIA

- Receiving any other investigational agents =< 6 months prior to Registration

- History of allergic reactions attributed to compounds of similar chemical or biologic composition to INO-8000 and INO-9012

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Intervention

Biological:
DNA Plasmid Encoding Interleukin-12 INO-9012
Given IM
Electroporation-Mediated Plasmid DNA Vaccine Therapy
Undergo electroporation
HCV DNA Vaccine INO-8000
Given IM
Other:
Laboratory Biomarker Analysis
Correlative studies
Quality-of-Life Assessment
Ancillary studies

Locations

Country Name City State
Puerto Rico University of Puerto Rico San Juan
United States Mayo Clinic in Florida Jacksonville Florida
United States Temple University Hospital Philadelphia Pennsylvania
United States Mayo Clinic Rochester Minnesota

Sponsors (3)

Lead Sponsor Collaborator
Mayo Clinic Inovio Pharmaceuticals, National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type Measure Description Time frame Safety issue
Other CD8 and CD4 T lymphocyte responses as measured by flow cytometry, and antibody responses, to HCV antigen for the dose levels determined to be safe The immune response comparisons will be made using descriptive statistics and graphical methods for both phases of the study. Descriptive statistics and simple scatter plots will be generated to review the continuous immune response data. For continuous immune response values, the actual and % change in the level of each of the biomarkers from baseline to post-baseline time points will be explored within each dose level/arm using Wilcoxon signed rank tests, and paired sample t-tests. Up to 26 weeks No
Other Percentage of participants with > 1 log decrease (or undetectable) in HCV RNA level The point estimate (and the associated 95% CIs) for primary immune response endpoint will be estimated within each arm and formally compared using a chi-squared test (or Fisher's exact test, if the data warrant). A logistic regression analysis will also be utilized to adjust for potential baseline covariates considered critical for this population. Up to 26 weeks No
Other Percentage of participants with end-of-treatment undetectable HCV RNA (EVR) for the dose levels determined to be safe The immune response comparisons will be made using descriptive statistics and graphical methods for both phases of the study. Descriptive statistics and simple scatter plots will be generated to review the continuous immune response data. For continuous immune response values, the actual and % change in the level of each of the biomarkers from baseline to post-baseline time points will be explored within each dose level/arm using Wilcoxon signed rank tests, and paired sample t-tests. 26 weeks Yes
Other SVR - undetectable HCV RNA The immune response comparisons will be made using descriptive statistics and graphical methods for both phases of the study. Descriptive statistics and simple scatter plots will be generated to review the continuous immune response data. For continuous immune response values, the actual and % change in the level of each of the biomarkers from baseline to post-baseline time points will be explored within each dose level/arm using Wilcoxon signed rank tests, and paired sample t-tests. 36 weeks No
Primary Incidence of dose-limiting toxicity, defined as an adverse event occurring after the initial vaccine administration, based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0 The percentage of participants who experience grade 3 or worse adverse events and administration-site reactions following each dose will be summarized using descriptive statistics across each dose level. Baseline to 26 weeks Yes
Primary Mean change of interferon-gamma production by peripheral blood mononuclear cells Change in production of interferon-gamma by peripheral blood mononuclear cells will be based on a one-way analysis of variance (ANOVA) model using data from all dose levels at the 2-sided 5% level. Mean change (and % change) and the associated 95% confidence intervals (CIs) in the production of IFN-gamma by peripheral blood mononuclear cells for all evaluable participants enrolled at each dose level will be computed, and compared across the dose levels in an exploratory fashion using graphical approaches, one-way ANOVA models etc. to ascertain a dose-response curve. Baseline to 26 weeks No
See also
  Status Clinical Trial Phase
Completed NCT01771653 - Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection N/A
Recruiting NCT03601546 - Feasibility of Implementing a Cohort of People Living With Hepatitis C in Vietnam
Completed NCT02362217 - A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination Phase 1
Completed NCT00513461 - Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection Phase 2
Active, not recruiting NCT02143401 - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT02247401 - Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt Phase 3
Completed NCT02582632 - A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults Phase 3
Terminated NCT01532908 - Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C Phase 2
Recruiting NCT01754961 - Effects of Vitamin D on Inflammation in Liver Disease Phase 2
Terminated NCT01465516 - Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir N/A
Completed NCT01265511 - Study of SCY-635, Pegasys and Copegus in Hepatitis C Phase 2
Completed NCT04042740 - Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection Phase 2
Not yet recruiting NCT05601518 - Efficacy and Safety of Coblopasvir Hydrochloride Capsules Combined With Sofosbuvir Tablets for the Treatment of Chronic HCV Infection: A Prospective, Multi-center Real-world Study.
Terminated NCT02429583 - Effects of Persistent Innate Immune Activation on Vaccine Efficacy Phase 4
Not yet recruiting NCT05506475 - Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam
Withdrawn NCT02112630 - Boceprevir in End Stage Renal Disease (ESRD) N/A
Terminated NCT01841502 - Interaction Between Paroxetine and Telaprevir Phase 2
Completed NCT02076100 - Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003) Phase 1
Completed NCT01803308 - A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection Phase 1
Terminated NCT01560468 - Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection Phase 1